Two-Day Session Synthesis: 6 of 7 Research Peptides Recommended by the FDA Pharmacy Compounding Advisory Committee for the Section 503A Bulks List Across Thursday July 23 and Friday July 24, 2026, With Only Emideltide (DSIP) Failing to Secure a Majority; All Six Wins Override the FDA Career-Staff Position and Represent the Broadest Advisory Endorsement of Compounding-Channel Peptides in the Committee's History; STAT News and Time Magazine Frame the Outcome as a Win for HHS Secretary Robert F. Kennedy Jr. and Continued Rulemaking Timeline of 6-18 Months Still Applies Before Actual Compounding-Pharmacy Access Changes
The two-day FDA Pharmacy Compounding Advisory Committee (PCAC) session closed Friday July 24, 2026 with 6 of 7 research peptides recommended for the Section 503A Bulks List. Day 1 wins: BPC-157 (8-6-1), KPV (8-6-1), TB-500 (8-6), MOTS-c (7-5-2). Day 2 wins: Semax (8-5), Epitalon (7-4). Day 2 rejection: Emideltide/DSIP. Every one of the 6 wins overrode the FDA career-staff briefing documents that recommended against adding any of the seven peptides. STAT News, Time Magazine, NPR, ABC News, Bloomberg, US News, The Hill, and Washington Times converged on the framing that HHS Secretary Robert F. Kennedy Jr.'s peptide-access push cleared a substantive advisory threshold. Panel composition itself was a substantive factor: eight new PCAC members were named June 29, with at least seven documented to have peptide-industry ties per STAT News. What still has to happen before actual compounding-pharmacy access changes: FDA leadership must review each vote, decide whether to accept it, publish a proposed rule in the Federal Register, run a 60-90 day public comment period, respond to comments, and publish a final rule with an effective date. Rulemaking typically takes 6-18 months per substance from the date the FDA decides to act.